Projects - BeNeBio

BeNeBio is a multicentric clinical study about dose reduction of biologics in patients with psoriasis.

When the psoriasis is extensive, some patients are eligible for treatment with biologics, drugs that are given via injections. For this study, psoriasis patients treated with the newest biologics - the interleukin (IL-) 17 and -23 inhibitors – will be studied. Biologics are usually prescribed in a fixed, standard dose. However, some patients might show an excellence response to the standard dose and show similar results with a lower dose.

The aim is to investigate if the dose can be reduced in patients with stable psoriasis who are using the normal, standard dose. It is important that the disease does not worsen due to dose reduction. A lower dose has advantages: it might lead to less side effects and it might lower the healthcare costs. With this study, we want to achieve that a part of the patients can be treated with less medication, while the effect on the skin remains positive.

The BeNeBio study is a collaboration between the departments of dermatology of the Radboudumc (Netherlands) and Ghent University Hospital (Belgium). The study is funded by ZonMW and KCE through a joint project. By collaborating, more research data can be collected. This might lead to better results.

For more information regarding the study, take a look on the dedicated BeNeBio website. For any study related questions, don't hesitate to reach out to benebio@uzgent.be

Made possible by: